A newly published clinical trial offers encouraging news for parents of children on the autism spectrum, demonstrating that a specialized, plant-derived cannabis extract can safely and effectively ease core symptoms of autism spectrum disorder. Published in the peer-reviewed journal Neurotherapeutics, “The Harmony Study” evaluated the safety and efficacy of a novel cannabinoid formulation in children and adolescents diagnosed with moderate to severe ASD. Australian researchers conducted a double-blind, randomized, placebo-controlled trial assessing fifty-four young participants who received either a twice-daily standardized extract containing precise ratios of CBD, CBDV, THC, and other minor cannabinoids, or a placebo for eight weeks.
The clinical results revealed significant improvements among participants who received the active cannabis extract compared to those in the control group. On average, patients taking the novel formulation experienced a two-point drop in overall disease severity on a seven-point scale, along with noticeable enhancements in anxiety levels, emotional regulation, social awareness, responsiveness, communication skills, and cognitive function. When participants in the placebo group were given the option to transition to the active treatment during a subsequent open-label phase, they experienced similar clinical gains.
Equally important for families evaluating new care options, the study highlighted an exceptional safety profile. Side effects associated with the extract were uniformly classified as mild, non-serious, and self-resolving, while caregivers consistently noted meaningful enhancements in overall family quality of life. These findings build on a growing body of scientific evidence worldwide supporting the therapeutic role of cannabinoids in managing neurodevelopmental disorders, offering parents a promising, research-backed look at the future of autism care.
Dabbin-Dad Newsroom
